1-4 of 4
Leonard C. Glass
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care 2014;37:2132–2140

Steve V. Edelman, Rong Liu, Jennal Johnson, Leonard C. Glass
Journal: Diabetes Care
Diabetes Care 2014;37(12):e263–e264
https://doi.org/10.2337/dc14-1900
Published: 08 November 2014
View article titled, Response to Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care 2014;37:2132–2140
Open the PDF for Response to Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care 2014;37:2132–2140 in another window
Journal Articles

AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes

Steve V. Edelman, Rong Liu, Jennal Johnson, Leonard C. Glass
Journal: Diabetes Care
Diabetes Care 2014;37(8):2132–2140
https://doi.org/10.2337/dc13-2664
Published: 12 July 2014
View article titled, AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes
Open the PDF for AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

Julio Rosenstock, MD, Sylvia K. Shenouda, PHD, Richard M. Bergenstal, MD, John B. Buse, MD, Leonard C. Glass, MD, Cory R. Heilmann, PHD, Anita Y.M. Kwan, MS, Leigh A. MacConell, PHD, Byron James Hoogwerf, MD
Journal: Diabetes Care
Diabetes Care 2012;35(5):955–958
https://doi.org/10.2337/dc11-1434
Published: 11 April 2012
View article titled, Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
Open the PDF for Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

Ralph A. DeFronzo, MD, Curtis Triplitt, PHARMD, Yongming Qu, PHD, Michelle S. Lewis, PHD, David Maggs, MD, Leonard C. Glass, MD
Journal: Diabetes Care
Diabetes Care 2010;33(5):951–957
https://doi.org/10.2337/dc09-1521
Published: 27 January 2010
View article titled, Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
Open the PDF for Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin in another window
Includes: Supplementary data